CLAIMS

1. A crystalline monohydrate of elobixibat.

2. The crystalline monohydrate of elobixibat according to claim 1 which is crystal modification IV of elobixibat, having an XRPD pattern, obtained with CuKα1-radiation, with peaks at º2θ positions 6.3 ± 0.2 and 19.4 ± 0.2.

3. The crystal modification according to claim 2, having an XRPD pattern, obtained with CuKα1-radiation, with peaks at º2θ positions 6.3 ± 0.2 and 19.4 ± 0.2 and one or more of the characteristic peaks:10.2 ± 0.2, 10.5 ± 0.2, 9.4 ± 0.2, 9.5 ± 0.2, 12.5 ± 0.2, 14.6 ± 0.2, 15.6 ± 0.2, and 23.3 ± 0.2.

4. Crystal modification IV of elobixibat according to claim 2, having an XRPD pattern, obtained with CuKα1-radiation, as shown in FIG. 1.

5. Crystal modification EtOH-1 of elobixibat, having an XRPD pattern, obtained with CuKα1-radiation, with peaks at º2θ positions 6.1 ± 0.2 and 18.9 ± 0.2.

6. Crystal modification EtOH-1 of elobixibat according to claim 5, having an XRPD pattern, obtained with CuKα1-radiation, as shown in FIG. 2.

7. Crystal modification MeOH-1 of elobixibat, having an XRPD pattern, obtained with CuKα1-radiation, with peaks at º2θ positions 6.2 ± 0.2 and 18.9 ± 0.2.

8. Crystal modification MeOH-1 of elobixibat according to claim 7, having an XRPD pattern, obtained with CuKα1-radiation, as shown in FIG. 8.

9. Crystal modification 1-PrOH-1 of elobixibat, having an XRPD pattern, obtained with CuKα1-radiation, with peaks at º2θ positions 6.1 ± 0.2 and 19.0 ± 0.2.

10. Crystal modification 1-PrOH-1 of elobixibat according to claim 9, having an XRPD pattern, obtained with CuKα1-radiation, as shown in FIG. 9.

11. Crystal modification 2-PrOH-1 of elobixibat, having an XRPD pattern, obtained with CuKα1-radiation, with peaks at °2θ positions 6.1 ± 0.2 and 19.0 ± 0.2.

12. Crystal modification 2-PrOH-1 of elobixibat according to claim 11, having an XRPD pattern, obtained with CuKα1-radiation, as shown in FIG. 10.

13. Crystal modification I of elobixibat, having an XRPD pattern, obtained with CuKα1-radiation, with peaks at °2θ positions 5.2 ± 0.2 and 10.0 ± 0.2.

14. Crystal modification I of elobixibat according to claim 13, having an XRPD pattern, obtained with CuKα1-radiation, as shown in FIG. 4.

15. The crystal modification according to any one of claims 2-4, for use in therapy.

16. The crystal modification according to any one of claims 13-14, for use in therapy.

17. A pharmaceutical composition comprising crystal modification IV of elobixibat according to any one of claims 2-4, together with a pharmaceutically acceptable diluent or carrier.

18. Use of crystal modifications MeOH-1, EtOH-1, 1-PrOH-1 and 2-PrOH-1 of elobixibat according to any one of claims 5-12 in a process for the preparation of crystal modification IV of elobixibat according to any of claims 2-4.